8 results
8-K
EX-99.1
NKTX
Nkarta Inc
21 Mar 24
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:15pm
Society of Hematology, of those patients who achieved CR/CRi, 3 of 4 remained in CR/CRi at 4 months as of the data cut off on October 31, 2023.
Fourth
8-K
EX-99.1
NKTX
Nkarta Inc
9 Nov 23
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:06pm
to present a poster at the American Society of Hematology annual meeting in December 2023 with follow-up data on the six patients from the June 2023
8-K
EX-99.1
NKTX
Nkarta Inc
9 Nov 22
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
4:03pm
, Nkarta presented preclinical data from its engineered NK cell platform in two posters at the annual meeting of the Society for Immunotherapy of Cancer
8-K
EX-99.1
NKTX
Nkarta Inc
17 Mar 22
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
4:11pm
engineered NK cell platform in four posters at the annual meeting of the Society for Immunotherapy of Cancer (SITC). The posters included data on CRISPR
8-K
EX-99.1
n15c18s8oo kfso
10 Nov 21
Nkarta Reports Third Quarter 2021 Financial Results and Business Update
4:14pm
10-K
f3f3onuc9s6jbavk8ba7
25 Mar 21
Annual report
12:00am
8-K
EX-99.2
jok3w1oxqo
12 Nov 20
Nkarta Reports Third Quarter 2020 Financial Results
4:08pm
- Prev
- 1
- Next